Skip to main content
. 2019 Feb 26;63(3):e02262-18. doi: 10.1128/AAC.02262-18

TABLE 3.

Activity of omadacycline and comparator antimicrobial agents for the main organisms from all geographic regions combined

Antimicrobial agent by organism or organism group (no. of isolates) MIC50 (mg/liter) MIC90 (mg/liter) Susceptibility or resistance (%) according to:
CLSIa
EUCASTa
S R S R
Staphylococcus aureus (689)
    Omadacycline 0.12 0.25 98.5b 0.0b
93.5c 1.5c
    Tigecycline 0.12 0.25 100.0d 100.0 0.0
    Doxycycline 0.25 8 78.5 4.8 62.0 26.6
    Tetracycline ≤0.5 >8 53.0 46.0 52.5 47.2
    Clindamycin 0.06 >2 68.2 31.5 68.1 31.8
    Daptomycin 0.25 0.25 99.9 99.9 0.1
    Levofloxacin 0.25 >4 63.0 36.9 63.0 37.0
    Linezolid 1 2 100.0 0.0 100.0 0.0
    Oxacillin 1 >2 56.6 43.4 56.6 43.4
    Trimethoprim-sulfamethoxazole ≤0.5 1 93.5 6.5 93.5 5.1
    Vancomycin 1 1 100.0 0.0 100.0 0.0
Enterococcus spp. (103)e
    Omadacycline 0.06 0.12 99.0f 0.0f
    Tigecycline 0.06 0.12 100.0 0.0
    Minocycline 8 >8 46.6 40.8
    Tetracycline >16 >16 40.8 58.3
    Ampicillin 2 >16 53.4 46.6 52.4 46.6
    Daptomycin 1 2 100.0
    Linezolid 1 2 99.0 0.0 100.0 0.0
    Vancomycin 1 >16 87.4 10.7 87.4 12.6
Streptococcus pneumoniae (392)
    Omadacycline 0.06 0.12 98.7g 0.0g
    Tigecycline 0.06 0.06 90.8d
    Tetracycline >4 >4 7.7 90.6 7.7 91.6
    Amoxicillin-clavulanic acid 2 >4 70.9 24.0
    Azithromycin >4 >4 5.9 94.1 5.9 94.1
    Ceftriaxone 1 >2 68.9g 14.0g 46.9 14.0
    Levofloxacin 1 2 99.0 1.0 99.0 1.0
    Linezolid 1 1 100.0 100.0 0.0
    Penicillin 2 4 35.2h 53.8h 35.2i 32.1i
67.9j 1.8j
Enterobacteriaceae (1,041)
    Omadacycline 2 8 88.9k 6.6k
    Tigecycline 0.25 1 95.8 0.2b 91.3 4.2
    Doxycycline 4 >8 52.7 34.8
    Tetracycline 16 >16 42.8 52.1
    Amikacin 2 4 95.3 4.3 94.0 4.7
    Ceftazidime 0.5 >32 66.8 29.4 58.8 33.2
    Ceftriaxone 0.5 >8 53.1 46.4 53.1 46.4
    Gentamicin 0.5 >16 68.3 30.9 68.0 31.7
    Imipenem ≤0.12 2 89.7 6.4 93.6 4.1
    Levofloxacin 0.5 >16 65.7 30.7 56.6 36.7
    Piperacillin-tazobactam 2 128 82.9 11.6 79.0 17.1
Acinetobacter baumannii (225)
    Omadacycline 4 8
    Tigecycline 4 8
    Doxycycline >8 >8 18.2 77.8
    Tetracycline >16 >16 11.2 87.9
    Amikacin >32 >32 23.1 74.7 20.9 76.9
    Cefepime >16 >16 14.2 81.3
    Gentamicin >16 >16 14.7 84.4 14.7 85.3
    Imipenem >8 >8 16.4 83.1 16.4 82.2
    Piperacillin-tazobactam >128 >128 13.4 85.3
Pseudomonas aeruginosa (300)
    Omadacycline >32 >32
    Tigecycline 8 >8
    Doxycycline >8 >8
    Amikacin 4 16 93.3 5.7 88.6 6.7
    Cefepime 2 >16 79.3 10.3 79.3 20.7
    Colistin 1 1 100.0 0.0 100.0 0.0
    Gentamicin 2 >16 81.7 13.3 81.7 18.3
    Imipenem 1 >8 68.3 29.0 71.0 23.3
    Piperacillin-tazobactam 8 >128 71.9 18.7 71.9 28.1
Haemophilus influenzae (181)
    Omadacycline 0.5 1 100.0g 0.0g
    Tigecycline 0.25 0.5 84.5d
    Tetracycline 0.5 8 85.6 14.4 85.6 14.4
    Amoxicillin-clavulanic acid 1 4 97.2 2.8 89.0 11.0
    Ampicillin 1 >8 56.4 40.3 56.4 43.6
    Azithromycin 1 2 91.2 0.6 8.8
    Ceftriaxone 0.008 0.03 100.0 96.7 3.3
    Levofloxacin 0.015 0.25 97.8 78.9 21.1
a

Criteria as published by CLSI 2018 and EUCAST 2018 (26, 27).

b

Using ABSSSI breakpoints, including MRSA, from FDA package insert (28).

c

Using CABP breakpoints for MSSA from FDA package insert (28).

d

Breakpoints from FDA package insert (31).

e

Organisms include Enterococcus avium (1), E. faecalis (48), E. faecium (52), and E. gallinarum (2).

f

Using ABSSSI breakpoints for E. faecalis from FDA package insert (28).

g

Using CABP breakpoints from FDA package insert (28).

h

Using oral breakpoints.

i

Using nonmeningitis breakpoints.

j

Using parenteral, meningitis breakpoints.

k

Breakpoints from FDA package insert revised 05/2018, K. pneumoniae and E. cloacae (ABSSSI) and K. pneumoniae only (CABP) (28).